FDA Sets PDUFA Date for Acoramidis in Heart Failure Indication
The FDA has set an action date of Nov. 29, 2024, to review acoramidis to treat patients with transthyretin amyloid cardiomyopathy.
The FDA has accepted BridgeBio’s new drug application (NDA) for acoramidis to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a type of heart failure in older adults. ATTR-CM is a rare disease that leads to a build-up of the protein transthyretin in the left ventricle of the heart, leading to a thickening of the heart muscle.
The agency has set a Prescription Drug User Fee Act (PDUFA) action date of Nov. 29, 2024. Regulators are not currently planning to hold an advisory committee meeting.
Acoramidis is an oral small molecule stabilizer of transthyretin. It was designed to mimic the protective effects of T119M mutation, which has been associated with reduced risk of vascular events.
The application was based on positive results from ATTRibute-CM, the phase 3 study, in which 421 patients received acoramidis and 211 patients received placebo. The trial allowed for patients to take Vyndamax (tafamidis) after month 12. Vyndamax was approved by the FDA in 2019 to treat adults with transthyretin mediated amyloidosis.
In the study, acoramidis met the primary endpoint, which included an analysis of all-cause mortality, then frequency of cardiovascular-related hospitalization, change from baseline in natriuretic peptide test and change from baseline in six-minute walk distance.
The trial used the win ratio, a method for reporting composite endpoints that gives priority to certain events. Patients in these trials are matched based on risk profiles and events are compared among the pairs and assigned a “win” if they meet the endpoint.
In the trial, acoramidis achieved an 81% on survival rate compared with 74% survival rate for patients taking placebo. Absolute risk reduction was 6.43% and the relative risk reduction was 25%. In terms of frequency of cardiovascular-related hospitalization, acoramidis achieved a relative risk reduction of 50%.
In the study, 37.3% of patients taking acoramidis experienced serious adverse events, and 5% of patients treated with acoramidis experienced treatment related serious adverse events that led to discontinuation.
BridgeBio presented data from the ATTRibute-CM trial at the American Heart Association (AHA) Scientific Sessions 2023 in November 2023.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
